BiomX Inc. will report its third quarter 2025 financial results and program updates on November 12, 2025, before the U.S. financial markets open. A conference call and live webcast will follow at 8:30 a.m. ET for investors and analysts. The company is a clinical-stage leader in natural and engineered phage therapies targeting specific pathogenic bacteria to treat chronic diseases. BiomX’s BOLT platform customizes phage compositions against bacterial targets. To participate in the call, register at least 5 minutes before the start. Non-questioning participants can listen via webcast. For more information, visit BiomX’s website.

Read more at GlobeNewswire: BiomX to Report Third Quarter 2025 Financial Results and